Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 5Recruiting 3Terminated 2Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 723Neoplasms 461Prostatic Neoplasms 398Carcinoma, Non-Small-Cell Lung 388Lung Neoplasms 311Leukemia, Myeloid, Acute 301Multiple Myeloma 270Colorectal Neoplasms 243Neoplasm Metastasis 240Pancreatic Neoplasms 238Leukemia 235Melanoma 217Lymphoma 213Precursor Cell Lymphoblastic Leukemia-Lymphoma 204Brain Neoplasms 195Recurrence 178Head and Neck Neoplasms 177Lymphoma, Non-Hodgkin 174Myelodysplastic Syndromes 168Leukemia, Lymphocytic, Chronic, B-Cell 168Ovarian Neoplasms 160Carcinoma, Hepatocellular 154Glioblastoma 149Carcinoma, Renal Cell 137Rectal Neoplasms 134Colonic Neoplasms 129Lymphoma, Large B-Cell, Diffuse 125Lymphoma, Follicular 125Hodgkin Disease 116Squamous Cell Carcinoma of Head and Neck 109

Interventions

pembrolizumab 1PT-100 dipeptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × Advanced Malignant Solid Neoplasm × Clear all
NCT04171219 2025-05-16

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
31 enrolled 15 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT04552704 2023-08-02

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

University of California, Davis

Phase 1/2 Terminated
3 enrolled 12 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡